Content Type: Article

  • HPE Miami 2023 | Mitigating Risk & Liabilities: Strategies for 100 Days Post-Close and Beyond

    HPE Miami 2023 | Mitigating Risk & Liabilities: Strategies for 100 Days Post-Close and Beyond

    ARTICLE

    HPE Miami 2023 | Mitigating Risk & Liabilities: Strategies for 100 Days Post-Close and Beyond

    March 8-9, 2023

    Read time: 3 min

    Key takeaways
    Overview

    During this session, this roundtable focused on steps that investors can take to promote compliance. Among other topics, there was discussion regarding the roles, responsibilities and best practices for those serving in board roles, including strategies to mitigate risk, both for sponsors and portfolio companies.

    Session panelists included:

    • Jamie Gelfman, Partner, McDermott Will & Emery
    • Ross Ronan, JD, BSN, CHC, CCEP, CMPE, Principal, Ronan Healthcare Consultants
    • David Saunders, Partner, McDermott Will & Emery
    • Laura McLane, Partner, McDermott Will & Emery (Moderator)
    In depth

    Key takeaways included:

    1. In an environment where scrutiny of private equity investors in healthcare has increased, it is imperative to focus on compliance from the top-down. What may seem like minor regulatory violations at the portfolio company level can become the basis for enforcement activity against both the company and the sponsor.
    2. The compliance mindset starts with the diligence process. If regulatory issues are revealed, it is crucial that they either be addressed pre-closing or there is a plan in place to address them post-closing. There are many ways to structure deals to account for compliance issues that need attention, but the key point is that if issues do arise, they cannot be ignored.
    3. After closing, compliance oversight starts with the Board of Directors. Deal team members who sit on boards should understand their responsibilities as board members, which are not the same as their responsibilities as employees of the sponsor. The board should ensure that the portfolio company has a good compliance program in place (and not one that is perfunctory or just “on paper”), that the portfolio company is receiving routine compliance reports from management/the compliance officer, and that any issues raised are swiftly and effectively addressed.
    4. While board members are not expected to become regulatory experts, they should have a general familiarity with the major types of legal and regulatory issues the portfolio company may face. These may include, among other issues, billing and coding issues, privacy and cybersecurity issues, US Food & Drug Administration issues and licensing and credentialing issues.
    5. The 100 days post-closing are a crucial time to tackle the low-hanging fruit that was highlighted in pre-closing diligence. Dealing with issues proactively and quickly materially enhances the value of a private equity sponsor’s investment, while failing to address them can materially detract from that value. In short, good compliance hygiene in healthcare investing allows sponsors to effectively protect their assets and reduces the risk that the sponsor will become the subject of enforcement scrutiny.
    Authors

    Jamie B. Gelfman

    Partner

    Miami

    David P. Saunders

    Partner

    Chicago

    Laura McLane

    Partner

    Boston

    More insights

  • DOJ and SEC Charge Healthcare Executive with Trading on Negative Information Known at the Time of Adopting Rule 10b5-1 Trading Plans

    DOJ and SEC Charge Healthcare Executive with Trading on Negative Information Known at the Time of Adopting Rule 10b5-1 Trading Plans

    ARTICLE / CLIENT ALERT

    DOJ and SEC Charge Healthcare Executive with Trading on Negative Information Known at the Time of Adopting Rule 10b5-1 Trading Plans

    March 8, 2023

    Read time: 5 min

    Key takeaways
    Overview

    On March 1, 2023, the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) charged a healthcare executive with insider trading based on material, non-public negative information known to the executive at the time he adopted two Rule 10b5-1 trading plans. (See the following articles: “CEO of Publicly Traded Health Care Company Charged for Insider Trading Scheme” and “SEC Charges Ontrak Chairman Terren Peizer With Insider Trading.”) In so doing, the DOJ and SEC alleged that the executive avoided more than $12.7 million in losses by selling shares in advance of the public release of the material information. The DOJ noted that this prosecution “represents the first time that the [DOJ] has brought criminal insider trading charges based exclusively on an executive’s use of 10b5-1 trading plans.” The actions came during the same week that the mandatory “cooling-off” periods imposed by the SEC pursuant to amendments to Rule 10b5-1 took effect. We previously issued guidance on the adoption of these limitations in our client alert “SEC imposes new restrictions on availability of rule 10b5-1 defense to insider trading.”

    In depth

    The DOJ’s and SEC’s actions focus on allegations that the executive had learned that his company’s relationship with its then-largest customer was increasingly tenuous at the time he adopted his first Rule 10b5-1 plan and sold nearly 600,000 shares worth more than $19.2 million. Even more compelling are the allegations that at the time the executive adopted a second plan, he learned that the same relationship with this significant customer was on the verge of being terminated. The SEC complaint is replete with quotations from emails detailing the customer’s eventual dissociation with the executive’s company.

    The executive’s sale of shares under the second plan included 45,000 shares for total proceeds of approximately $2 million that occurred within days before his company publicly announced that the customer terminated its contract with the executive’s company. The actions allege that the Rule 10b5-1 plans adopted by the executive did not include a cooling-off period before trades under the plan could commence. The executive allegedly shopped for a broker who would set up the plan without a cooling-off period since a cooling-off period was not required by the rules at the time. In this regard, SEC Chairman Gary Gensler’s prior push for reforms was prescient, particularly with respect to the minimum 90-day cooling-off period for directors and officers adopted by the SEC. Chairman Gensler previously expressed concern that the lack of a cooling-off period is viewed by “some bad actors…as a loophole to participate in insider trading” and advocated that a mandatory cooling-off period would help alleviate insider trading concerns since the information would either become stale or publicly disclosed by the time the cooling-off period expired. The minimum 90-day cooling-off period, had it been in place at the time of the executive’s adoption of his second plan, would have delayed the sale of his shares until after his company disclosed the termination of the material contract.

    The absence of the affirmative defense of Rule 10b5-1 serves as an underpinning of the actions. According to Rule 10b5-1(c)(1)(ii), the affirmative defense is only available if the trading arrangement was entered into at a time when the insider was not aware of material, non-public information, in good faith and not as part of a plan or scheme to evade the prohibitions of the rule. Based on the facts alleged in the actions, the executive established the two trading plans while he was aware of material, non-public information about his company and did not adopt the plans in good faith but as part of a scheme to evade insider trading prohibitions.

    KEY TAKEAWAY

    A key takeaway from the above actions is that prosecutors will be vigilant in probing abuses of the purported shield against exposure from insider trading offered by Rule 10b5-1. To ensure the continued availability of the affirmative defense against allegations of insider trading, we recommend that companies review and update their insider trading policies to address the treatment of Rule 10b5-1 plans, particularly focusing on preclearance procedures designed to provide reasonable assurance that insiders who adopt Rule 10b5-1 plans do so at a time when they do not possess material, non-public information.

    Authors

    Eric Orsic

    Partner

    Chicago

    Thomas P. Conaghan

    Partner

    Washington, DC, New York – One Vanderbilt Avenue

    More insights

  • HPE Miami 2023 | Preparing Your Company for a Transaction

    HPE Miami 2023 | Preparing Your Company for a Transaction

    ARTICLE

    HPE Miami 2023 | Preparing Your Company for a Transaction

    March 8-9, 2023

    Read time: 3 min

    Key takeaways
    Overview

    The first session of HPE Miami 2023 put a spotlight on key considerations for founders as they navigate the pre-transaction process.

    This session featured insights from the following panelists:

    • Ibrahim Barakat, Partner, McDermott Will & Emery
    • Scott Davis, Director, Provident Healthcare Partners
    • James Gorayeb, Partner, Deloitte
    • Melissa Price, Partner, McDermott Will & Emery
    In depth

    Key takeaways included:

    1. Connecting with an investment banker is one of the most important steps a founder should consider when preparing for a sale. Investment bankers can help founders identify the right set of advisors for their company’s situation. They can also serve as a sounding board, provide comparisons to past deals and act as guides throughout the transaction’s pre-marketing, marketing, diligence and closing stages. An investment banker can help shoulder some of the transactional workload and provide valuable touchpoints throughout the deal process.
    2. Most buyers expect a sell-side quality of earnings analysis. A sell-side quality of earnings analysis allows founders and their advisors to identify areas of value and potential risks early in the diligence process, and as such is one of the most important aspects of a due diligence process. Not passing the buy-side quality of earnings analysis and other finance-related issues are among the most common reasons that deals do not close.
    3. Founders should think about maximizing tax efficiency as early as possible. Founders are in the best position to create tax efficiency for future transfers before the deal starts, ideally a year or two before the sale process begins. Engaging an estate planning lawyer early can allow a founder to maximize the use of their gift tax exemption.
    4. Negotiation of the letter of intent is typically the moment in the transaction when a founder has the greatest leverage. Having a lawyer review the letter of intent and discuss key terms such as rollover equity can help founders to fully understand and effectively negotiate key deal terms.
    Authors

    Melissa Price

    Partner

    Miami, Boca Raton

    More insights

  • HPE Miami 2023 | Trends and Developments in Fund Finance: Oh My!

    HPE Miami 2023 | Trends and Developments in Fund Finance: Oh My!

    ARTICLE

    HPE Miami 2023 | Trends and Developments in Fund Finance: Oh My!

    March 8-9, 2023

    Read time: 4 min

    Key takeaways
    Overview

    During this session, Partner Anh Lee moderated a panel that provided key insights on current fund financing trends, including the latest in net asset value (NAV) facilities.

    Session panelists included:

    • Tom Hoge, Managing Director, Silicon Valley Bank
    • Alexandra Woodcock, Partner, Mourant
    In depth

    Key takeaways included:

    1. The market for fund financing has increased significantly in recent years, driven in part due to access to liquidity being of specific concern for private equity borrowers in the current economy. The year 2022 saw a particularly sharp uptick in demand for these facilities, with a distinct growth in demand for NAV facilities. Factors influencing this increased demand include a difficult fundraising market and diminished remaining capital funds, with borrowers turning to these facilities for follow-on investments to existing platforms and structures. Many are calling this “the year of the add-on.”
    2. Borrowers can expect some key differences in the terms of a NAV facility as compared to traditional capital call facilities. The underwriting for lenders under a capital call facility is based on the availability and ability of the lender to call on uncalled capital commitments to fund loan obligations, whereas the underwriting for lenders under a NAV facility is primarily based on the value of the portfolio investment of the fund borrower. The panelists suggested that to qualify for a NAV loan, a “good” NAV facility borrower candidate must have at least five portfolio company assets with no concentrations above 25%.. Other key differences include (1) a longer underwriting process, with the average NAV facility taking eight to 10 weeks to complete the initial underwriting; (2) third-party valuations will be required in an overwhelming majority of cases; (3) a smaller-sized facility (typically 5% to 15% loan-to-value); (4) frequently, at least 50% utilization will be required at closing and (5) generally, higher pricing.
    3. Though, historically, fund financing has been primarily structured as bilateral deals, they are now being syndicated in greater numbers. Lenders are reassessing deals and their risk tolerance given current macroeconomic factors; simply put, a fund financing deal that would have previously been booked as a bilateral deal is now being syndicated. Pros of this trend include access to larger facilities for borrowers, wider access to banking products and lower rates (as compared to a bilateral deal). On the other hand, administrative fees, arranger fees and legal fees will all be higher. Another potential drawback of syndication is that having more lenders could create issues at maturity if a borrower wants to renew but a particular lender wants to exit. This is of special concern for fund financing, as the typical tenor of a capital call facility is only one to two years.
    4. Many lenders are offering fund financing facilities as relationship builders to the existing funds and clients they work with, and the rise in demand has led to lenders becoming increasingly creative and collaborative to meet the varied needs of their clients. Determining the right utilization for a client’s specific use is key in structuring these deals, and lenders are actively involved in helping their clients find the right size facility in this market. The rise in NAV facilities showcases lenders’ willingness to offer broader options to meet their clients’ needs.
    Authors

    Anh B. Lee

    Partner

    Chicago

    More insights

  • HPE Miami 2023 | Fundraising in a Challenging Environment

    HPE Miami 2023 | Fundraising in a Challenging Environment

    ARTICLE

    HPE Miami 2023 | Fundraising in a Challenging Environment

    March 8-9, 2023

    Read time: 3 min

    Key takeaways
    Overview

    During this session, Partner Luc Jansen moderated a panel that provided an overview of the current fundraising market and offered insights into which strategies are yielding successful outcomes.

    Session panelists included:

    • Brad Fisher, Managing Director, Private Investments, Thrivent Financial
    • Marc Lohser, Managing Director, HQ Capital
    • Brendan Pack, Managing Director, iCapital

     

    In depth

    Key takeaways included:

    1. Despite current market conditions, institutional investors have tried to be consistent in terms of the deployment of funds, while adjusting in process and strategy to be more selective and thoughtful in the allocation of funds. In terms of strategy, the conviction behind investments has remained. Consistency has resonated across the space, however, institutions have opted for a more tactical approach, sticking to funds’ main sectors and remaining opportunistic when the right situation arises. Some institutional investors might reduce allocations to private equity as their private equity portfolio has grown when compared to their public equity portfolio given that stocks are down significantly.
    2. Deal flow has remained fairly consistent, but there has been a shift inward to a focus on improving current businesses and platforms, leading to an increase in secondary transactions and add-ons to increase earnings before interest, taxes, depreciation and amortization (EBITDA) organically.
    3. The current market presents a challenge to fundless sponsors and new managers. Investors have gravitated toward well-established funds with a demonstrable track record of success. This has been especially reflected in the healthcare private equity space, where it has become more important than in any other sector to have industry expertise.
    4. The healthcare sector continues to be a main focus for institutions, with heavy interest on healthcare technology sparked by COVID-19.
    5. Institutions have increasingly used technology to improve their investment process as advancements have allowed them to store and use information in more diverse ways, increasing the ability to better source investors and opportunities and better evaluate deals and how they fit into current portfolios. However, on the co-investment side, things remain an extremely relationship-driven business.
    6. High-net-worth investing in private equity might not change or even pick up now that public equities are lower in value and high-net-worth investors are seeking yield elsewhere. Also, private equity sponsors might be more interested in high-net-worth capital since some institutional investors are pulling back.

     

    Authors

    Luc Jansen

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • AI Advertising: The FTC Prepares for Battle

    AI Advertising: The FTC Prepares for Battle

    ARTICLE / CLIENT ALERT

    AI Advertising: The FTC Prepares for Battle

    March 7, 2023

    Read time: 4 min

    Key takeaways
    Overview

    On February 27, 2023, the Federal Trade Commission (FTC) published guidance aimed at artificial intelligence (AI) advertising claims. After the massively successful beta release of OpenAI’s ChatGPT, many companies, big and small, are promoting AI as part of their products and many consumers are seeking AI products. However, several companies and consumers do not have a firm understanding of AI or its capabilities. The FTC instructs those who are marketing and selling products in this space to beware: “for FTC enforcement purposes […] false or unsubstantiated claims about a product’s efficacy are our bread and butter.” It’s important for companies that market technology, specifically AI, or utilize the technology itself to understand the FTC’s evolving enforcement of AI claims to avoid future penalties.

    Section 5 of the FTC Act prohibits unfair and deceptive acts and practices. In advertising, this means that all claims, whether explicit or implied, must be truthful and substantiated. Claims are viewed through the eyes of the reasonable consumer and all reasonable interpretations must be truthful, accurate and substantiated. What constitutes adequate substantiation depends on the specific claim itself.

    Specifically, as it relates to AI, advertisers are warned not to exaggerate the features of their AI products or promise that the AI-enabled version will perform better than a non-AI product unless there is sufficient, adequate substantiation. The FTC also notes that even some AI purveyors may not know the capabilities or limitations of their products. Nonetheless, the FTC says AI vendors “need to know about the reasonably foreseeable risks and impact of [the] AI product before putting it on the market.” Further, if the product does not actually use AI, “FTC technologists and others can look under the hood and analyze other materials to see if what’s inside matches up with your claims.”

    This is not the first guidance on AI that the FTC has promulgated. Earlier FTC AI guidance from April 2021 focused on fairness and equity, and a lengthy June 2022 report at the direction of US Congress studied “how artificial intelligence (AI) may be used to identify, remove, or take any other appropriate action necessary to address a wide variety of specified online harms.” [quotation marks omitted]. Additionally, just last month, the FTC announced the launch of a new Office of Technology, further signaling the FTC’s focus on increased enforcement in the technology sector. The new office is designed to “strengthen the FTC’s ability to keep pace with the technological challenges in the digital marketplace by supporting the agency’s law enforcement and policy work.”

    With the latest published guidance, it’s clear that the FTC will be scrutinizing any advertising and offerings in the AI space for truthfulness, as well as requiring that AI vendors understand the capabilities and limitations of their products.

    In depth
    Authors

    Jason D. Krieser

    Partner

    Dallas

    Shawn C. Helms

    Partner

    Dallas

    More insights

  • Preparing for the End of the COVID-19 Emergency: Coverage of COVID-19 Vaccines

    Preparing for the End of the COVID-19 Emergency: Coverage of COVID-19 Vaccines

    ARTICLE / CLIENT ALERT

    Preparing for the End of the COVID-19 Emergency: Coverage of COVID-19 Vaccines

    March 6, 2023

    Read time: 4 min

    Key takeaways
    Overview

    Our April 3, 2023, webinar explored the impacts that the end of the PHE and NE will have on employee benefit plans and what actions employers and benefit plan sponsors should be taking to prepare. Watch the “How Employers Should Prepare for the End of the Covid-19 National and Public Health Emergencies” webinar recording to learn more.


    The Biden administration has announced its intent to end the COVID-19 National Emergency (NE) and the COVID-19 Public Health Emergency (PHE) on May 11, 2023 (read our prior client alert, “Preparing for the end of the COVID-19 emergency: Coverage of COVID-19 testing,” for more information). A topic of great debate has been the requirement and the coverage of COVID-19 vaccines. This article explores what will happen to the coverage of vaccines at the end of the PHE and NE. 

    In depth

    COVID-19 VACCINE COVERAGE REQUIREMENTS

    Since March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act has required health plans and issuers to cover COVID-19 vaccines without cost-sharing, even when provided by out-of-network providers, during the PHE. Health plans and issuers have been required to cover COVID-19 vaccines within 15 days after any vaccine becomes recommended by the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention or receives a rating of “A” or “B” classification recommendation from the United States Preventive Services Task Force (USPSTF). Separately, the Affordable Care Act (ACA) generally requires coverage of vaccines recommended by the ACIP and the USPSTF as preventative care without cost-sharing. If a COVID-19 vaccine is provided by an out-of-network provider, however, health plans may begin to impose cost-sharing and certain prior authorization and medical management requirements. As a result, after the PHE, COVID-19 vaccines will still need to be covered without cost-sharing except in the case of an out-of-network provider.

    ACTION ITEMS

    Due to the ongoing requirements of the ACA, there will be minimal actions that employers need to take after the PHE ends regarding vaccine coverage. The primary changes are that ACIP-recommended COVID-19 vaccines should be covered immediately instead of after a 15-day hold period and that health plans can decide whether to apply cost-sharing, prior authorization and medical management requirements to COVID-19 vaccines obtained from an out-of-network provider.  A summary of material modifications and/or plan amendment may be required for any changes the health plan makes. Even for plans that are not subject to the ACA, such as grandfathered health plans, participants cannot be balance billed if a vaccine dose was purchased by the federal government. However, the federal government has not received additional funds from Congress to continue to purchase more vaccines for some time. Employers and plan sponsors should stay up to date on developments, as there may be some questions regarding which vaccines must be covered without cost-sharing as more vaccines become available.

    For any questions regarding the end of the PHE and/or NE, please contact your regular McDermott lawyer or one of the authors.

    Authors

    Jacob M. Mattinson

    Partner

    Chicago

    Sarah G. Raaii

    Partner

    Chicago

    More insights

  • DOJ Announces Major Changes to Corporate Compliance Program Evaluation Criteria, Including Compensation and Personal Messaging Applications

    DOJ Announces Major Changes to Corporate Compliance Program Evaluation Criteria, Including Compensation and Personal Messaging Applications

    ARTICLE / CLIENT ALERT

    DOJ Announces Major Changes to Corporate Compliance Program Evaluation Criteria, Including Compensation and Personal Messaging Applications

    March 6, 2023

    Read time: 11 min

    Key takeaways
    Overview

    During speeches on March 2 and 3, 2023, at the American Bar Association (ABA) National Institute on White Collar Crime (the 2023 White Collar Conference), Deputy Attorney General (DAG) Lisa Monaco, Assistant Attorney General (AAG) for the Criminal Division Kenneth A. Polite, Jr. and other US government officials announced significant changes to the US Department of Justice’s (DOJ) Evaluation of Corporate Compliance Programs (ECCP) and continued to emphasize the importance of effective and robust compliance policies.

    First, DAG Monaco and AAG Polite announced DOJ’s first-ever Pilot Program on Compensation Incentives and Clawbacks (Pilot Program) requiring companies to “develop compliance-promoting criteria within its compensation and bonus systems.” The new Pilot Program—as well as announcements relating to additional resource commitments to corporate criminal enforcement—are part of DOJ’s broad initiative to “invigorate” corporate criminal enforcement and empower companies to invest “in compliance, in culture, and in good corporate citizenship.” 

    Second, in evaluating a company’s compliance policies relating to identifying, reporting, investigating and remediating potential misconduct, prosecutors should now consider a company’s policies and procedures relating to messaging applications (including third-party encrypted messaging applications), ephemeral messages, other communications platforms and the use of personal devices. Companies that do not adopt policies to preserve and produce such messages could jeopardize their ability to obtain a favorable resolution.    

    Third, DOJ repeatedly emphasized that it now considers corporate criminal enforcement to be a national security concern, even stating that sanctions enforcement “is the new FCPA.” DOJ announced a “surge of resources” to the Criminal and National Security divisions to address sanctions evasion and export controls and expects corporate compliance programs to specifically address these issues. 

    These changes come on the heels of DOJ’s announcement, last month, of a single corporate voluntary self-disclosure policy for every US Attorneys’ Office nationwide, and are simply the latest evidence of the Biden Justice Department’s substantial focus on corporate criminal enforcement. In speech after speech at the ABA White Collar Conference, DOJ officials emphasized the benefits to those companies willing to adopt changes to their compliance programs—and their approach to learning of potential misconduct—to account for these new policies.  

    In depth

    COMPENSATION POLICIES SHOULD “PROMOTE” COMPLIANCE AND DETER MISCONDUCT

    To “shift the burden of corporate malfeasance away from uninvolved shareholders onto those more directly responsible,” DOJ now expects executive and employee compensation structures to incentivize compliance and punish misconduct. As DAG Monaco explained, “Nothing grabs attention or demands personal investment like having skin in the game, through direct and tangible financial incentives.”

    DOJ has revised the ECCP, which was last updated in 2020, to reflect DOJ’s new focus on executive compensation. The ECCP now includes specific language addressing compensation structures and their “important role in fostering a compliance culture.” When evaluating corporate compliance programs and potential criminal resolutions, prosecutors may now consider whether companies have incentivized compliance by designing compensation systems that defer or escrow certain compensation tied to conduct that is consistent with company values and policies. Prosecutors can also consider whether provisions for recoupment or reduction of compensation due to misconduct or compliance violations are maintained and enforced by company policies. Finally, prosecutors are now directed to examine whether compensation schemes are indicative of a positive compliance culture, considering the human resource process, disciplinary measures, consistent application, and a financial incentive system that rewards compliance-promoting behavior and punishes non-compliant or unethical conduct.

    DAG Monaco and AAG Polite also announced DOJ’s new Pilot Program Regarding Compensation Incentives and Clawbacks. It will be a three-year initiative applicable to all corporate matters handled by the Criminal Division and will be effective as of March 15, 2023. The Pilot Program has two primary components:

    Under the first component, prosecutors will now be directed to consider corporate compensation structures more closely. Every corporate resolution entered into by the Criminal Division will require the company to implement certain compliance-related criteria in its compensation and bonus system. The company will also be required to report its implementation of these criteria to prosecutors.

    The Pilot Program suggests that the criteria could include:

    1. A prohibition on bonuses for employees who do not satisfy compliance performance requirements.

    2. Disciplinary measures for employees who violate applicable law and others who meet both of the following conditions:

    a. Had supervisory authority over the employee(s) or business area engaged in the misconduct.

    b. Knew of, or were willfully blind to, the misconduct.

    3. Incentives for employees who demonstrate full commitment to compliance processes.

    Prosecutors will have the discretion to fashion further “appropriate requirements” based on the facts and circumstances of the case, including applicable foreign and domestic laws, and they must also consider how the company has structured its existing compensation system.

    Second, the Criminal Division will offer fine reductions to companies that seek to clawback compensation from employees who engage in misconduct relating to the conduct under investigation, had supervisory authority over the employee(s) or a business unit engaged in the misconduct, or were willfully blind to the misconduct. If a company—in good faith—has started a process to recoup or claw back such compensation before the time of resolution, prosecutors may reduce a criminal fine in the amount of the recouped compensation. If a company’s good-faith attempt to recoup compensation is unsuccessful, prosecutors may still reduce a criminal fine up to 25% of the amount of compensation that the company sought to claw back.

    Indeed, DOJ has already begun requiring companies to implement changes to compensation policies as part of criminal resolutions. For example, in December 2022, Danske Bank pleaded guilty to bank fraud and agreed to forfeit more than $2 billion dollars. As part of the plea agreement, Danske Bank agreed to significantly revise its executive bonus system. Each bank executive will now be evaluated on whether that executive’s department is following the bank’s compliance program and is in compliance with all applicable laws and regulations. Executives who receive a failing compliance score will be ineligible for a bonus.

    These changes to the ECCP and the Pilot Program are all part of DOJ’s ongoing efforts to increase “individual accountability.” But these new DOJ policies regarding compensation are not designed to address solely those executives and employees who engaged in actual misconduct. Rather, as AAG Polite explained, DOJ also expects corporate compensation policies to address “those who had supervisory authority over the employees or business area engaged in the misconduct.”

    THE IMPORTANCE OF PRESERVING DATA FROM PERSONAL DEVICES AND MESSAGING APPLICATIONS

    Last fall, in another series of speeches, DOJ put companies on notice of the department’s increasing concern about the rise and common use of certain messaging applications, including encrypted and ephemeral messaging applications such as WhatsApp, Signal and Telegram, by company employees for business purposes. DOJ expressed its concerns about these types of unofficial communications, which typically do not occur on company-provided or monitored programs, and its concerns that such communications might be inconsistent with an effective corporate compliance program and the need to access necessary data and information for audits, reviews or investigations, when necessary.

    The newly revised ECCP specifically addresses corporations’ approaches to the use of personal devices and messaging applications, including encrypted and ephemeral messaging applications. Due to the growing prevalence of these messaging applications and corporate “Bring Your Own Device” (or “BYOD”) polices, DOJ now “expects companies to update their policies and practices accordingly.”

    Perhaps more important, when evaluating a company’s compliance program, prosecutors will now be required to evaluate the company’s “policies and procedures governing the use of personal devices, communication platforms, and messaging applications.” These policies should be “tailored to the corporation’s risk profile and specific business needs” and ensure that business-related communications are accessible and preserved “to the greatest extent possible.”  Prosecutors are also required to consider how these policies and procedures have been communicated to employees and whether they are enforced “on a regular and consistent basis.”

    The revised ECCP also contains detailed questions prosecutors should address when evaluating a company’s policies. For example, prosecutors are now directed to determine whether a corporation’s policy allows the company to review business communications on personal devices and messaging applications and whether employees are required to transfer messages from messaging applications to company recordkeeping systems in order to preserve and retain them. Similarly, prosecutors should evaluate whether there are consequences for employees who refuse to provide access to business data on personal devices and whether any employees have been disciplined for providing such access.

    In announcing the changes, AAG Polite also explained that when content from personal devices or non-company-provided messaging applications has not been produced during an investigation, prosecutors will no longer “accept that at face value” and will instead demand information regarding the company’s preservation and deletion policies and ability to access personal devices. Ultimately, whether a company has preserved and produced communications from ephemeral messaging applications and personal devices “may well affect the offer it receives to resolve criminal ability” and should therefore “be top of mind” as companies refine existing policies.

    CORPORATE CRIMINAL ENFORCEMENT IS NOW BEING CONSIDERED A NATIONAL SECURITY ISSUE

    In addition to announcing the above changes to existing policies, DAG Monaco, AAG Polite and other government officials repeatedly stated that DOJ now considers corporate criminal enforcement, including sanctions enforcement and export controls, to be a critical nation security concern. DAG Monaco explained that “[i]ncreasingly, corporate criminal investigations carry profound national security implications,” specifically referred to “sanctions [as] the new FCPA” and noted that these issues “should now be at the top of every company’s risk-compliance chart.” AAG Polite emphasized the “intersection of national security and corporate prosecution” during his separate speech.

    Finally, Assistant Attorney General for National Security Matthew G. Olsen, Assistant Secretary for Export Enforcement at the US Department of Commerce’s Bureau of Industry and Security (BIS) Matthew S. Axelrod, and Treasury Department Director of the Office of Foreign Assets Control (OFAC) Andrea Gacki all made clear that the increased focus on sanctions and export controls and the associated enterprise risks, which have come to the forefront during Russia’s invasion of Ukraine, are here to stay.

    To address these national security issues going forward, DAG Monaco announced a “surge of resources” to both its Criminal and National Security divisions. The National Security Division will be hiring more than 25 new prosecutors, including its first-ever Chief Counsel for Corporate Enforcement, to investigate and prosecute sanctions evasion, export control violations and other economic crimes. DAG Monaco and AAG Polite also announced that DOJ would be making “substantial investments” in DOJ’s Bank Integrity Unit, which has in the past decade imposed more than $13 billion in penalties in 10 corporate criminal resolutions with financial institutions for sanctions violations, despite having only 12 attorneys.

    DOJ made clear that it now expects companies in a wide range of industries, such as transportation, FinTech, banking, defense, energy and agriculture, to implement compliance policies specifically designed to address sanctions evasion and export control violations. Indeed, AAG Olsen repeatedly referenced the importance of having a strong sanctions and export control compliance regime.

    As DOJ ramps up enforcement in these areas, it is thus critical that companies make the necessary modifications to their existing compliance policies to account for this increased risk. If sanctions are in fact “the new FCPA,” companies must take it just as seriously.

    KEY TAKEAWAYS

    The continuing and clear import of these collective statements is two-fold:

    First, compliance programs matter, and companies will be expected to devote time and resources to making sure existing policies now address issues such as compensation and encrypted and ephemeral messaging applications, among other issues.

    Second, the pressure on companies to self-report misconduct has never been greater. As DAG Monaco stated, “Where your company discovers criminal misconduct, the pathway to the best resolution will involve prompt, voluntary self-disclosure to the DOJ.” Throughout the 2023 White Collar Conference, DOJ officials, including Monaco and Polite, provided examples of companies who benefited from prompt disclosure, cooperation and remediation.

    Companies assessing their compliance programs in light of these most recent announcements should give particular thought to:

    • Examining compensation models throughout the organization, including whether adjustments to such policies and/or employment agreements are needed in light of DOJ’s recent announcements.
    • Reviewing policies addressing the use of personal devices or messaging applications (including standard text messaging) for business communications that may occur outside of formal company-provided (and monitored) communication methods.
    • Reviewing and revising document retention and preservation policies, including understanding the current technology used by employees to conduct business and ensuring that companies have a means to access and preserve such communications.
    • Focusing on sanctions and export controls, even where such issues would not traditionally affect the company.
    • Ensuring that current programs help proactively identify and investigate wrongdoing so that the business can take advantage of the benefits of self-disclosure where appropriate.
    • Developing policies and procedures around how to quickly engage the right people in discussions to determine whether self-disclosure is appropriate—from compliance, to legal, to the board—before such an issue arises.

    By making these changes, companies will put themselves in the best position to identify misconduct early and preserve the ability to self-report and obtain the benefit of a favorable resolution with DOJ should misconduct occur and self-reporting be appropriate.

    Authors

    Julian L. André

    Partner

    Los Angeles

    Edward B. Diskant

    Partner

    New York – One Vanderbilt Avenue

    James Durkin

    Partner

    Chicago

    Paul M. Thompson

    Partner

    Washington, DC

    Benton Curtis

    Partner

    Miami

    More insights

  • CMS Issues Guidance on Medicare Prescription Drug Inflation Rebate Program

    CMS Issues Guidance on Medicare Prescription Drug Inflation Rebate Program

    ARTICLE / CLIENT ALERT

    CMS Issues Guidance on Medicare Prescription Drug Inflation Rebate Program

    March 3, 2023

    Read time: 5 min

    Key takeaways
    Overview

    On February 9, 2023, the Centers for Medicare and Medicaid Services (CMS) issued initial program guidance related to the implementation of the Prescription Drug Inflation Rebate Program. The rebate program was authorized under Sections 11101 (as to Medicare Part B) and 11102 (as to Medicare Part D) of the Inflation Reduction Act (IRA). The guidance lays out key information on CMS’s new industry-changing authority over prescription drug pricing. Of particular interest to stakeholders are the forthcoming changes to claim-level identification of drugs obtained through the 340B Drug Pricing Program and changes that could prompt a new federal False Claims Act enforcement risk related to manufacturer price reporting.

    In depth

    Under the IRA, drug manufacturers are required to pay a rebate to Medicare if they raise the price for certain drugs faster than the rate of inflation. For part B drugs, price changes will be measured based on the average sales price. For part D drugs, price changes will be measured based on the average manufacturer price. The base year for measuring cumulative price changes relative to inflation is 2021. If prices increase higher than the rate of inflation, manufacturers will be required to pay the difference in the form of a rebate to Medicare. The rebate amounts will be calculated and invoiced by CMS, with such calculation equal to the total number of units sold in Medicare multiplied by the amount, if any, by which a drug’s price in a given year exceeds the inflation-adjusted price. After receipt of the invoice, manufacturers will have 30 days to pay the rebate, which will be deposited in the Medicare Supplementary Medical Insurance trust fund. The rebates apply to certain Medicare Part B and Medicare Part D drugs, and CMS issued guidance on each program.

    In the Part B rebate guidance, CMS seeks comment and explains several aspects of the Medicare Prescription Drug Inflation Rebate Program, including the identification of Part B rebatable drugs, the computation of beneficiary coinsurance amounts, the determination of the number of drug units to be used for calculating rebates, the method for identification of 340B drugs to exclude them from the rebate calculations, and the enforcement mechanisms to be used to ensure integrity of the rebate program.

    In the Part D rebate guidance, CMS seeks comment and explains implementation mechanisms for the Part D inflation rebates on various topics, including the identification of the Part D rebatable drug billing units for the prescription claim and prescription drug event records, the method for identification of 340B drugs to exclude them from the rebate calculations, the reduction of waiver of rebate amounts in the event of supply chain disruptions, and the enforcement mechanisms to be used to ensure integrity of the rebate program.

    340 Program Implications

    In the guidance on 340B programs for Part B claims, CMS describes and seeks comments on methods that will be used in 2023 to identify 340B drugs in addition to the requirement of the “JG” or “TB” modifier on all claim lines for separately payable Part B drugs beginning on January 1, 2024. For 2023, CMS will identify and exclude 340B drugs from the rebate calculations using the following methods:

    Claim lines billed with the “JG” and “TB” modifiers

    • All separately payable drug units on institutional claims billed by critical access hospitals, Maryland waiver hospitals and non-excepted off-campus provider-based departments
    • All drug units on professional claims for Medicare suppliers listed by the Health Resources and Services Administration as participating in the 340B Program, by Employer Identification Number.

    As to Part D claims, the rebate requirement does not begin until 2026, but CMS has nevertheless proposed a method for identifying 340B drugs dispensed to Medicare Part D beneficiaries. CMS believes that the existing National Council for Prescription Drug Programs (NCPDP) Telecommunications Standard Version D.0 for pharmacy claims includes a field where a 340B indicator could be provided, although CMS acknowledged that this is not widely used. CMS stated that code “20” can be used to identify 340B drugs. CMS further acknowledged that this indictor can only be used prospectively and noted that some 340B claims may be identified retrospectively. CMS remarked that there is an existing NCPDP transaction (N1) to retrospectively identify 340B drugs. CMS seeks comments on whether the preferred mechanism is the use of these existing NCPDP fields and transactions to identify 340B drug units billed to Medicare Part D, or whether another reliable option is available.

    Enforcement Implications

    In each memo, CMS explains enforcement mechanisms to be used for the rebate program, including the issuance of civil monetary penalties equal to at least 125% of the calculated rebate amount. This new program also could give rise to federal False Claims Act allegations related to drug price reporting. Manufacturers have experienced similar claims related to price reporting in the Medicaid rebate program. With Medicare drug pricing also becoming tied to average sales price or average manufacturer price, pricing and discounting practices may take on more importance from a False Claims Act risk perspective.

    CMS solicits comments on both the Part B and Part D guidance by March 11, 2023. All comments can be submitted to IRARebateandNegotiation@cms.hhs.gov.

    * * *

    McDermott is closely following the rebate provisions as well as all CMS developments under the IRA. Please do not hesitate to reach out to the McDermott team if you have any questions about the IRA rebate provisions or if you would like assistance in preparing comments to the guidance.

    Authors

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    More insights

  • Advanced Planning Can Reduce Your Tax Burden When Buying Property or Moving to the United States

    Advanced Planning Can Reduce Your Tax Burden When Buying Property or Moving to the United States

    ARTICLE / CLIENT ALERT

    Advanced Planning Can Reduce Your Tax Burden When Buying Property or Moving to the United States

    March 2, 2023

    Read time: 4 min

    Key takeaways
    Overview

    Moving to or purchasing real estate in the United States as a nonresident requires careful consideration of US federal income, estate and state and local tax laws. Inbound US federal tax planning involves analyzing these laws to ensure compliance with tax obligations and the maximization of tax benefits.

    One important aspect of inbound tax planning is determining tax residency status. The US income tax system distinguishes between residents and nonresidents for tax purposes. A resident is typically someone who is a citizen, holds a green card or spends enough time in the United States to meet the so-called substantial presence test. Nonresidents are individuals who do not meet the criteria for tax residency.

    As a nonresident, an individual may still be subject to US federal income tax on income earned in the United States. For example, rental income from US property or source income may be subject to US income tax. Nonresidents are also subject to US estate and gift tax on their situated assets, such as real estate located in the United States.

    In addition to federal tax considerations, nonresidents must also consider state and local tax obligations. Most states and localities impose their own income, property and sales tax, among other taxes. In some cases, nonresidents may be subject to state and local taxes in addition to federal taxes. However, nonresidents can also take advantage of state and local tax incentives, such as tax credits and deductions, to reduce their overall tax liability.

    The estate tax is the most expensive tax in the US tax code and thus is another important consideration for individuals who are not domiciled in the United States. If a non-domiciliary dies with a US situated asset, such as real estate located in the country, the estate may be subject to US estate tax. The US estate tax is imposed on the fair market value of the situated assets at the time of the non-domicile’s death less an exemption amount that is only $60,000. However, a non-domiciliary may be able to minimize US estate tax liability through proper estate planning and the use of tax treaties.

    For nonresidents looking to obtain a green card, citizenship or otherwise become domiciled in the United States, income and estate tax planning becomes even more crucial prior to changing residence because the individual will be subject to US income and estate tax on the individual’s worldwide assets.

    In conclusion, US federal tax planning is crucial for nonresidents considering moving to the United States or purchasing real estate in the country. Understanding US tax laws and taking advantage of available tax benefits can minimize tax liability and prevent penalties for noncompliance. In addition to federal tax considerations, nonresidents must also consider state and local tax obligations and estate tax implications. To navigate the complexities of the US tax system, nonresidents should seek guidance from qualified tax professionals.

    In depth
    Authors
    More insights